Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The FDA has not yet decided on the shortage status of Lilly's tirzepatide, allowing compounding pharmacies to continue making and selling versions of the weight-loss therapy. A patient death in a Rett syndrome trial led Neurogene to drop the high-dose arm but continue with a lower dose. AstraZeneca is seeking full approval for its anticoagulation reversal drug Andexxa despite safety concerns from an advisory committee. In other news, Donald Trump's controversial cabinet picks, including RFK Jr. for HHS head, are seen as a "team of self-promoters" that could create uncertainty in the biopharma environment. SignalChem Biotech offers kinase drug discovery solutions, supporting researchers with enzyme and assay development services. Additionally, Merck's former asthma drug Singulair is potentially being linked to mental health problems, Sonata Therapeutics is laying off employees, and Amneal has received FDA approval for a generic GLP-1 drug. Job opportunities in biopharma are also available at companies like Amgen and Daiichi Sankyo.